Top Banner
ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia
26

ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

Dec 25, 2015

Download

Documents

Abel Shaw
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

ICCS e-Newsletter CSI Spring 2013

David A Westerman, MBBS FRACP FRCPA

Department of Pathology

Peter MacCallum Cancer Centre

Melbourne, Australia

Page 2: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Clinical History:

• A 52 year Caucasian man presents with pancytopenia for investigation, and a previous history of “T cell lymphoma”.

Page 3: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Peripheral Blood:

• CBCNormal Range– WBC: 0.5 x 109/l (4.0 – 11.0)– RBC: 2.86 x 1012/l (4.5 – 6.5)– Hgb: 9.0 g/dl (13.0 – 18.0)– Hct: 27.0 % (40.0 –

54.0)– MCV: 95.0 fl (80.0 – 96.0)– MCH: 32.0 pg (27.0 – 32.0)– MCHC: 32.9 g/dl (31.0 –

35.0)– RDW: 17.2% (11.7 – 15.7)– Plts: 25 x 109/l (150 – 400)

Page 4: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Peripheral Blood:

• CBC Differential – Granulocytes: 75%– Lymphocytes: 9%– Monocytes: 11% – Eosinophils: 2%

Page 5: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Clinical History:

• Bone marrow aspirate and trephine biopsy were performed.

• Flow cytometric immunophenotyping was performed on the bone marrow aspirate and the results from selected 8-color tubes are provided for review.

Page 6: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:

• Acquired FACS Canto II, analyzed with Kaluza

Page 7: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:

Initial gating strategies excluded doublets and debris

Further gating to include WBC’s and then a more “targeted” gated population based on an unusual CD45 vs SSC plot, in this case – “mononuclear gate”

Page 8: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:

56% of mononuclear cells gated are CD2+, while T cells account for only 4%

An expanded monocytic population is also identified with weak (but normal) CD4 expression (green)

Page 9: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:

CD2 vs CD3 allows separation of the NK cell population (black) and monocytes (green) in this case.Normal CD4+ and 8+ T cells can also be seen (mustard colour and blue)

Page 10: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:

CD2+ and 16/56+ NK cells (black), monocytes in green, residual T cells in mustard and light blue

Page 11: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:

NK cells are CD94+bright, 26+bright, 4-, 27+

Normal T cells

Page 12: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Studies:• Normal NK plot expressions

Normal expression of pooled normal donorsNK cells are in black, CD4+T cells mustard, CD8+ T cells in blue

Page 13: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI - Flow Cytometric Conclusion:

1. NK cells 56% of mononuclear gate expressing: CD2+, 3-, 4-, 5 partial, 7-, 8-, 16/56+, 26+ bright, 27-, 94+ bright, TCR αβ- & γδ-

2. Monocytes –normal expression compared to controls with this panel of markers but expanded in number

Page 14: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – cont.

• Correlation with morphology and subsequently immunohistochemistry was performed

Page 15: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – morphology

The aspirate quality was poor. A trephine touch is depicted showing numerous large, immature haematopoietic precursors

Page 16: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – morphology

H & E section x 40 magnification

Page 17: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – morphology

H & E section x 200 magnification; Effacement by an undifferentiated population of large blast-like cells

Page 18: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – morphology

CD2 demonstrates a dominant positive population, including mitotic figures

Page 19: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

CD3 shows cytoplasmic staining, in keeping with staining of CD3 epsilon chains of NK cells

e-CSI – morphology

Page 20: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – morphology

TIA shows a significant positive population, while some granzyme positivity was also seen (not shown), in keeping with the cytotoxic function of NK cells

Page 21: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – morphology

• EBV ISH is not a validated in our mercuric chloride fixed trephines, so was not tested

• TP53 IHC (not shown) showed positivity in about 20% of cells

• Insufficient material was available for cytogenetics

• TCR gene rearrangement studies were polyclonal

Page 22: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – Diagnosis

• Aggressive NK-cell leukaemia• Reactive monocytosis

Page 23: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – Aggressive NK-cell leukaemia

• This is a rare disorder with a preponderance in Asian and South American populations, and young to middle aged

• There is a strong association with EBV• Patients present with fever, cytopenias,

constitutional symptoms, leukaemic cells, DIC, or haemophagocytic syndrome. Skin involvement is uncommon

Page 24: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – Aggressive NK-cell leukaemia

• Morphologically: NK cells in this disorder vary from typical large granular lymphocyte morphology to atypical forms with folded nuclei, and nucleoli to frank blasts

• The typical phenotype is CD2+ CD3- CD3ε+ CD56+ CD57- CD16+ CD11b+

• FAS ligand (CD95) is found on neoplastic cells, and also in the serum

• T cell receptor genes are germline

Page 25: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – Aggressive NK-cell leukaemia

• >90% cases are EBV positive• Karyotypic anomalies vary and include 11q,

6q, 17p deletions• The prognosis is poor and median survival

measureable in just a few months• Typically the disease is refractory to aggressive

chemotherapy

Page 26: ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.

e-CSI – References• Chan JKC, Jaffe ES, Ralfkiaer E et al. WHO Classification of Tumours

of Haematopoietic and Lymphoid Tissues. 4TH edition, pp276-277.• Dearden CE, Johnson R, Pettengell R et al. Guidelines for the

management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153, 451–485.

• Kawa-Ha K, Ishihara S, Ninomiya T et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Inves 1989; 84: 51-55.

• Kwong YL, The Diagnosis & management of extranodal NK/T cell lymphoma, nasal-type and aggreesive NK-cell leukemia. J Clin Exp Hematopath. 2011; 51: 21-27.

• Suzuki R, Suzumiya J, Nakamura S et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763–770.